Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Esperion Theraptc (ESPR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,127,714
  • Shares Outstanding, K 26,908
  • Annual Sales, $ 0 K
  • Annual Income, $ -201,810 K
  • 60-Month Beta 2.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 14.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 1.32
  • Number of Estimates 5
  • High Estimate 3.89
  • Low Estimate 0.61
  • Prior Year -1.73
  • Growth Rate Est. (year over year) +176.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.03 +6.97%
on 04/18/19
44.29 -5.73%
on 04/23/19
+0.12 (+0.29%)
since 03/25/19
3-Month
39.03 +6.97%
on 04/18/19
54.94 -24.01%
on 03/14/19
-2.95 (-6.60%)
since 01/25/19
52-Week
33.06 +26.29%
on 05/03/18
73.33 -43.07%
on 04/30/18
-27.50 (-39.71%)
since 04/25/18

Most Recent Stories

More News
Moore Kuehn Encourages Esperion Therapeutics, Inc. Investors to Contact Law Firm for Possible Claims Against Officers and Directors

Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating whether certain officers and directors of Esperion Therapeutics, Inc. (NASDAQ: ESPR) breached...

ESPR : 42.17 (+0.62%)
Relatively Good Performance Detected in Shares of Esperion Therape in the Biotechnology Industry (ESPR , PTLA , LXRX , EPZM , RARE )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

ESPR : 42.17 (+0.62%)
LXRX : 5.73 (-0.69%)
PTLA : 35.58 (-0.50%)
Esperion to Present at the Needham & Company 18th Annual Healthcare Conference

Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated...

ESPR : 42.17 (+0.62%)
Watch for Esperion Therape to Potentially Pullback After Gaining 6.67% Yesterday

Esperion Therape (NASDAQ:ESPR) traded in a range yesterday that spanned from a low of $42.59 to a high of $42.90. Yesterday, the shares gained 6.7%, which took the trading range above the 3-day high...

ESPR : 42.17 (+0.62%)
Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol Lowering and Reduced hsCRP in Statin Intolerant Patients

MUNICH and ANN ARBOR, Michigan, April 2, 2019 PRNewswire/ -- Daiichi Sankyo Europe GMbH (hereafter, 'Daiichi Sankyo') and Esperion Therapeutics announced today that results from the 345 patient, 24-week,...

ESPR : 42.17 (+0.62%)
Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results

- Study 3 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Patients Considered Statin Intolerant -

ESPR : 42.17 (+0.62%)
Esperion Therapeutics (ESPR) Down 12.9% Since Last Earnings Report: Can It Rebound?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ESPR : 42.17 (+0.62%)
Esperion Therape Set to Possibly Rebound After Yesterday's Selloff of 3.73%

Esperion Therape (NASDAQ:ESPR) traded in a range yesterday that spanned from a low of $39.44 to a high of $40.95. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of...

ESPR : 42.17 (+0.62%)
Esperion Therape Falls 6.57% on Heavy Volume: Watch For Potential Rebound

Esperion Therape (NASDAQ:ESPR) traded in a range yesterday that spanned from a low of $44.83 to a high of $48.17. Yesterday, the shares fell 6.6%, which took the trading range below the 3-day low of...

ESPR : 42.17 (+0.62%)
Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions

-Study 2 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP-

ESPR : 42.17 (+0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ESPR with:

Business Summary

Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan.

See More

Key Turning Points

2nd Resistance Point 44.07
1st Resistance Point 42.99
Last Price 42.17
1st Support Level 41.34
2nd Support Level 40.77

See More

52-Week High 73.33
Fibonacci 61.8% 57.95
Fibonacci 50% 53.19
Fibonacci 38.2% 48.44
Last Price 42.17
52-Week Low 33.06

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar